

Session 7: Beyond pathology of breast cancer in 2015

Chairs: Giuseppe Viale (Italy), Hervé Bonnefoi (France)

- **The special case of “equivocal” pathological biomarkers (ER, PgR and HER2): Implications for breast cancer treatment (Fraser W. Symmans, USA)**
- **BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? (Geoffrey J. Lindeman, Australia)**
- **The changing role of ER in endocrine resistance (C. Kent Osborne, USA)**
- **Developing Ki-67 as a useful marker (Carsten Denkert, Germany)**
- **Discussion**

Webcasts



<http://bcc14.oncoletter.ch>